<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01406548</url>
  </required_header>
  <id_info>
    <org_study_id>CBPS804A2203</org_study_id>
    <nct_id>NCT01406548</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Assess the Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is designed to provide information on the safety, tolerability, pharmacokinetics
      (PK) and bone biomarker response following multiple BPS804 administration in multiple dosing
      regimens. This information will permit a comparison of the possible risks and benefits of
      different dosing regimens of the study drug to enable optimal doses and dose intervals to be
      tested in subsequent studies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to month 9 in bone mineral density at the lumbar spine for the individual BPS804 groups and pooled placebo arms.</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The number (percent) of subjects experiencing adverse events or serious adverse events</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline during 9 months of serological bone biomarkers for the individual BPS804 groups and pooled placebo arms.</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of the PK profile of BPS804: area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>260 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of the PK profile of BPS804: time to reach the maximum Characterization of the PK profile of BPS804: maximum plasma concentration (Cmax)</measure>
    <time_frame>260 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of the PK profile: time to reach the maximum concentration (Tmax)</measure>
    <time_frame>260 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of the PK profile of BPS804: half-life (T1/2)</measure>
    <time_frame>260 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Osteopenia</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>BPS804 dosing frequency 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo dosing frequency 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BPS804 dosing frequency 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo dosing frequency 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BPS804 dosing frequency 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo dosing frequency 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BPS804</intervention_name>
    <arm_group_label>BPS804 dosing frequency 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo dosing frequency 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BPS804</intervention_name>
    <arm_group_label>BPS804 dosing frequency 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo dosing frequency 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BPS804</intervention_name>
    <arm_group_label>BPS804 dosing frequency 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo dosing frequency 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women (natural or surgically induced menopause)

          -  Low bone mineral density (BMD), as defined by a T score or equivalent BMD absolute
             value (g/cm2) for lumbar spine of between -2.0 and -3.5, inclusive

          -  Body mass index (BMI) must be within the range of 18 to 35kg/m2. Subjects must weigh
             between 45 and 120kg inclusive to participate.

          -  25-(OH) vitamin D serum level of â‰¥ 15ng/ml

          -  Serum calcium within normal limits

        Exclusion Criteria:

          -  Subjects with suspected neural foraminal stenosis (e.g., cervical, spinal, lumbar), or
             history of Bell's palsy, cranial nerve disorders, temporomandibular joint and muscle
             disorders.

          -  Subjects who have an increased baseline risk of osteosarcoma: Paget's disease of the
             bone or unexplained and clinically significant elevations of alkaline phosphatase
             and/or subjects who have received radiation therapy involving the skeleton.

          -  Subjects with any known bone diseases other than postmenopausal osteoporosis.

          -  Subjects with a history of an osteoporotic fracture (e.g., vertebral fracture,
             fragility fracture of the wrist, radius, humerus, hip, or pelvis).

          -  Subjects who are regularly using or have regularly used agents affecting bone
             metabolism:

               -  Calcitonin, estrogen, SERMs (raloxifene, Tamoxifen, etc.), Tibolone progestin, or
                  androgens within the last three (3) months prior to screening.

               -  Any oral bisphosphonate, lithium chloride, fluoride or systemic
                  glucocorticosteroids (p.o. or i.v.) where the total dose exceeds 750 mg of
                  prednisone or equivalent within the last year prior to screening.

               -  Any previous use of denusomab (ProliaTM), parathyroid hormone (ForteoTM), and/or
                  PTH analogs, strontium ranelate, or parenteral formulations of bisphosphonates.

          -  Current disease(s) known to influence calcium metabolism including
             hyperparathyroidism, hypoparathyroidism, hypocalcemia or hypercalcemia.

          -  Any disease, abnormality or deformation of the spine (e.g., scoliosis, ankylosing
             spondylitis, osteophytes) or hip (e.g., joint prosthesis) which would preclude the
             proper acquisition of a lumbar spine DXA (L1-L4) or femur DXA, respectively.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801-2811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2011</study_first_submitted>
  <study_first_submitted_qc>July 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2011</study_first_posted>
  <last_update_submitted>February 18, 2015</last_update_submitted>
  <last_update_submitted_qc>February 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteopenia</keyword>
  <keyword>osteoporosis</keyword>
  <keyword>low bone mineral density</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

